Now serving Florida and Georgia · Licensed providers · Discreet shipping
The Good Life Collective
Safety

Safety, in plain words.

Updated October 30, 2026. Safety information for every prescription program. Read it before your online visit, and ask your licensed provider about anything unclear.

Compounded medications

Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed. At The Good Life Collective, compounded semaglutide, tirzepatide, NAD+, sermorelin, glutathione, GHK-Cu cream and Biest lotions are compounded.

Report a side effect

Message your care team through your account, or email support@tglcwellness.com. You can also report to the FDA MedWatch program at fda.gov/medwatch. In an emergency, call 911.

Semaglutide Weight Program

  • The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain, most often when starting or increasing the dose.
  • Do not use it if you or a family member has had medullary thyroid cancer, or if you have multiple endocrine neoplasia type 2 (MEN 2). Tell your provider about any neck lump, trouble swallowing or hoarseness.
  • Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration and allergic reactions. Severe stomach pain that does not go away needs urgent care.
  • Not for use during pregnancy or while trying to conceive. Tell your provider before any surgery or procedure with anesthesia.
  • Compounded dosing is measured differently from brand-name pens. Follow the dose and volume on your pharmacy label exactly; dosing errors are the most common problem the FDA reports with compounded GLP-1s.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A personal or family history of medullary thyroid cancer, or MEN 2
  • Pregnancy, trying to conceive or breastfeeding
  • A history of pancreatitis or type 1 diabetes, unless your provider decides otherwise

Sources: Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, N Engl J Med (2021), MedlinePlus, Semaglutide Injection, FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, NIDDK, Prescription Medications to Treat Overweight and Obesity, FDA, Compounding and the FDA: Questions and Answers. Program page.

Tirzepatide Weight Program

  • The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain, most often when starting or increasing the dose.
  • Do not use it if you or a family member has had medullary thyroid cancer, or if you have multiple endocrine neoplasia type 2 (MEN 2). Tell your provider about any neck lump, trouble swallowing or hoarseness.
  • Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration and allergic reactions. Severe stomach pain that does not go away needs urgent care.
  • Not for use during pregnancy or while trying to conceive. Tell your provider before any surgery or procedure with anesthesia.
  • Compounded dosing is measured differently from brand-name pens. Follow the dose and volume on your pharmacy label exactly; dosing errors are the most common problem the FDA reports with compounded GLP-1s.
  • Tirzepatide can make birth control pills less effective for 4 weeks after starting and after each dose increase. Ask your provider about a backup method.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A personal or family history of medullary thyroid cancer, or MEN 2
  • Pregnancy, trying to conceive or breastfeeding
  • A history of pancreatitis, unless your provider decides otherwise

Sources: Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity, N Engl J Med (2022), MedlinePlus, Tirzepatide Injection, FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, NIDDK, Prescription Medications to Treat Overweight and Obesity, FDA, Compounding and the FDA: Questions and Answers. Program page.

Microdose GLP-1

  • The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain, most often when starting or increasing the dose.
  • Do not use it if you or a family member has had medullary thyroid cancer, or if you have multiple endocrine neoplasia type 2 (MEN 2). Tell your provider about any neck lump, trouble swallowing or hoarseness.
  • Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration and allergic reactions. Severe stomach pain that does not go away needs urgent care.
  • Not for use during pregnancy or while trying to conceive. Tell your provider before any surgery or procedure with anesthesia.
  • Compounded dosing is measured differently from brand-name pens. Follow the dose and volume on your pharmacy label exactly; dosing errors are the most common problem the FDA reports with compounded GLP-1s.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A personal or family history of medullary thyroid cancer, or MEN 2
  • Pregnancy, trying to conceive or breastfeeding
  • Anyone expecting the results seen with full weight-loss doses

Sources: FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, MedlinePlus, Semaglutide Injection, MedlinePlus, Tirzepatide Injection, FDA, Compounding and the FDA: Questions and Answers. Program page.

Sublingual Tirzepatide Drops

  • The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain, most often when starting or increasing the dose.
  • Do not use it if you or a family member has had medullary thyroid cancer, or if you have multiple endocrine neoplasia type 2 (MEN 2). Tell your provider about any neck lump, trouble swallowing or hoarseness.
  • Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration and allergic reactions. Severe stomach pain that does not go away needs urgent care.
  • Not for use during pregnancy or while trying to conceive. Tell your provider before any surgery or procedure with anesthesia.
  • Hold the drops under the tongue as your label directs. Do not swallow them right away.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A personal or family history of medullary thyroid cancer, or MEN 2
  • Pregnancy, trying to conceive or breastfeeding
  • Anyone who needs the evidence base of a studied, injectable dose

Sources: FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, FDA, Compounding and the FDA: Questions and Answers, MedlinePlus, Tirzepatide Injection. Program page.

Lipotropic MIC + B12

  • Possible effects include injection-site pain, mild diarrhea, itching and, rarely, allergic reactions.
  • Injections go under the skin with a small needle, following the written directions that come with your prescription. Common effects include redness, stinging or a small bump where you inject. Never share or reuse needles, and use a sharps container.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A known allergy to cobalt, vitamin B12 or any ingredient
  • Leber's disease (an inherited eye condition), because B12 can worsen it
  • Pregnancy or breastfeeding unless your provider approves

Sources: NIH Office of Dietary Supplements, Vitamin B12 Fact Sheet for Consumers, FDA, Compounding and the FDA: Questions and Answers. Program page.

NAD+

  • Commonly reported effects include flushing, nausea, headache, injection-site stinging and a feeling of chest tightness, especially if injected quickly.
  • The nasal spray can cause nasal irritation or a runny nose.
  • The FDA has received reports of reactions to NAD+ injections made with ingredients not suitable for sterile use, which is why prescriptions are filled only by state-licensed pharmacies.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • Pregnancy or breastfeeding
  • Anyone who has reacted badly to NAD+ before

Sources: Radenkovic and Verdin, Clinical Evidence for Targeting NAD Therapeutically, Pharmaceuticals (2020), FDA, FDA reminds compounders to use ingredients suitable for sterile compounding, FDA, Compounding and the FDA: Questions and Answers. Program page.

Sermorelin

  • Possible effects include injection-site redness or swelling, flushing, headache, dizziness and trouble sleeping.
  • Injections go under the skin with a small needle, following the written directions that come with your prescription. Common effects include redness, stinging or a small bump where you inject. Never share or reuse needles, and use a sharps container.
  • Sermorelin can be prohibited in tested sport. Check the WADA Prohibited List if you compete.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • Active cancer or a history of cancer unless your provider approves
  • Pregnancy or breastfeeding
  • Untreated thyroid disease

Sources: Walker, Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?, Clin Interv Aging (2006), FDA, Compounding and the FDA: Questions and Answers. Program page.

Glutathione

  • Possible effects include injection-site discomfort, bloating, cramps and, rarely, allergic reactions.
  • The nasal spray can cause nasal irritation.
  • Glutathione is not a skin-lightening or detox treatment, and this program is not offered for those uses.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • Pregnancy or breastfeeding
  • Asthma, unless your provider approves (inhaled forms have triggered wheezing)
  • A known allergy to glutathione

Sources: Richie et al., Randomized controlled trial of oral glutathione supplementation on body stores of glutathione, Eur J Nutr (2015), FDA, Compounding and the FDA: Questions and Answers. Program page.

GHK-Cu Copper Peptide Cream

  • Stop using it and contact your care team if you develop redness, stinging, itching, swelling or a rash.
  • Patch test on a small area first if your skin is reactive.
  • For external use only. Avoid eyes and lips.
  • Compounded medications are prepared by a state-licensed 503A pharmacy for an individual patient. They are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before they are dispensed.

Not for:

  • A known copper allergy or allergy to an ingredient
  • Broken, infected or freshly treated skin unless your provider says otherwise
  • Pregnancy or breastfeeding, where there is not enough data

Sources: Pickart and Margolina, Regenerative and Protective Actions of the GHK-Cu Peptide, Int J Mol Sci (2018), FDA, Compounding and the FDA: Questions and Answers. Program page.